Viloria-Petit and colleagues have observed the acquired resistance of tumor cells to anti-EGFR monoclonal antibodies associated with increased levels of VEGF, accompanied by an increase in angiogenic potential in vitro and tumor angiogenesis in vivo [26]. This evidence concerns the gene EGFR and neoplasm.